myeloMATCH: Precision Medicine Trials

MyeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice) is a group of precision medicine clinical trials for people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

MyeloMATCH consists of an initial screening study and multiple treatment trials. In the screening study, people with newly diagnosed MDS or AML will have blood and bone marrow samples collected. These samples will be analyzed for genetic changes commonly seen in MDS and AML. Based on the findings from the genetic analysis, participants will then be assigned to a trial testing treatments that target the specific mutations in their tumors or that may be particularly active because of the genetic makeup of the cancer. 

Participants who do not match with a treatment study in MyeloMATCH will receive standard therapy for their cancer and will be considered for other MyeloMATCH treatment trials that could offer appropriate therapy for them. 

MyeloMATCH trials are organized into four “tiers,” with each tier providing trial options at a different stage along the patient’s cancer treatment journey:

  • Tier 1 trials offer initial induction therapy for newly diagnosed patients
  • Tier 2 trials treat patients for residual disease after initial therapy
  • Tier 3 trials offer consolidation therapy or stem-cell transplant
  • Tier 4 trials treat progressively lower levels of residual disease that may remain

As an enrolled patient completes a course of treatment, new specimens will be collected and sent for testing. If that testing shows the patient's disease has been significantly reduced, a patient may be assigned to a new trial in a later tier.

The myeloMATCH tier structure is illustrated below.

 

 

 

 

 

 

 

 







 

New myeloMATCH treatment trials will be opened regularly.
The treatment trials below are now open and enrolling.

  • MM1OA-EA02, led by the ECOG-ACRIN Cancer Research Group:
    A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
     
  • MM1YA-CTG01 (AL6), led by the Canadian Cancer Trials Group:
    A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
     
  • MM1YA-S01, led by the SWOG Cancer Research Network:
    A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial

The following treatment trial will open in late October.

  • MM1MDS-A01, led by the Alliance for Clinical Trials in Oncology:
    A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Treatment Trial
  • Clinical Trial Summary

MyeloMATCH is supported by the NCI, and the MyeloMATCH screening protocol is coordinated by the SWOG Cancer Research Network. MyeloMATCH includes treatment trials developed and conducted by Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer Research Network. MyeloMATCH trials are conducted within the NCI’s National Clinical Trials Network and the NCI Community Oncology Research Program, and include collaborating personnel from BMT Clinical Trials Network, Children's Oncology Group, and NRG Oncology.